Differential Cytokine Levels in Adults Induced by a Novel Candidate TB Boost Vaccine, MVA85A-According to Previous BCG Vaccination Status

Patrick K. Owiafe1, Philip C. Hill1,2, Hannah B. Ibanga1,3, Roger H. Brookes1,4, Helen McShane1, Jayne S. Sutherland5 and Martin O.C. Ota1

1Vaccinology Theme, Medical Research Council (MRC) Unit, Fajara, The Gambia
2Centre for International Health, University of Otago, New Zealand
3Paediatrics, Queen’s Hospital, Belvedere Road, Burton on Trent, UK
4Sanofi Pasteur, Connaught Campus, West Toronto, Ontario, Canada
5The Jenner Institute, University of Oxford, Roosevelt Drive, Oxford, UK

Abstract

MVA85A is a candidate boost vaccine for TB. A previously reported study showed no differences in response to MVA85A in 10 BCG vaccinated (BCG+) and 11 BCG naive (BCG-) adult Gambians. Here we evaluated the effect of pre-existing plasma cytokines in both groups before and after MVA85A vaccination on the vaccine-induced immune response. Pre-vaccination levels of IL-8 were higher in BCG+ subjects, whilst MCP-1 levels were lower compared to BCG- . Following MVA85A vaccination, concentrations of IL-8, IL-18, IL-12(p70) and MCP-1 were differentially induced between BCG+ and BCG- groups. The implications of these findings depend on their role in TB pathogenesis.

Keywords: Tuberculosis; Cytokines; MVA85A; BCG

Introduction

Tuberculosis (TB) remains a major public health concern worldwide, with more than 2 million deaths every year, particularly in sub-Saharan Africa and South East Asia [1]. This disease burden demonstrates that although BCG protects against severe forms of TB in children it is incomplete [2]. However, due to some other non-specific beneficial effects such as the prevention of childhood mortality, allergies and promotion of immune responses to other Expanded Programme of Immunisation (EPI) vaccines [3-5], one current intervention strategy is to develop a new vaccination regimen that incorporates BCG, instead of replacing it.

Modified Vaccine virus Ankara expressing antigen 85A from Mycobacterium tuberculosis (M.tb) (MVA85A) is the most clinically advanced candidate vaccine developed to boost the effects of BCG. MVA85A was safe well tolerated and immunogenic when administered to adult volunteers in the UK, The Gambia and South Africa [6-8]. Interestingly, in The Gambian study, the immunogenicity of MVA85A in BCG vaccinated (BCG+) and BCG naive (BCG-) adults was comparable, in contrast to studies in the UK where immunogenicity was higher in BCG vaccinated subjects [6]. Furthermore in South Africa, the immunogenicity of MVA85A in BCG vaccinated adults was also comparable to that seen in BCG naïve adults [8]. These findings suggest that MVA85A may boost cumulative mycobacterial exposure which is comprised of exposure to BCG, non-tuberculous mycobacteria and M.tb, and that the contribution of BCG to this cumulative mycobacterial exposure is less relevant in adults in TB endemic countries. To gain a better understanding of the relevance of baseline anti-mycobacterial immunity, we examined the cytokine and chemokine profiles in plasma obtained before and after MVA85A vaccination according to the presence or absence of a BCG scar in these healthy Gambian adults that have been previously reported [7].

Methods

Study population

This study was conducted between 2003 and 2005 and the setting and inclusion/exclusion criteria have been previously described [7].

10 subjects with a visible BCG scar (an indicator of BCG vaccination status for BCG [7]) and another 11 without evidence of a scar of BCG vaccination were included in the study. The groups did not differ significantly with respect to age, height, weight and Mantoux skin test and all subjects were HIV seronegative. None of the subjects had a previous history of asthma, diabetes or TB and their chest X-rays were normal. After written informed consent, blood samples were taken before and after MVA85A vaccination into heparinised tubes and processed to obtain peripheral blood mononuclear cells and plasma. Plasma samples were aliquoted and stored at -200C until required for the measurement of cytokines in this study. Clinical trial number NCT00423839 (clinicaltrials.gov).

Multiplex bead array assay

Plasma samples before and one week after vaccination were analysed using a Bio-Pad 17-plex kit according to the manufacturer’s instructions. 50 μl of bead suspension was added to each well and washed twice. 50 μl of samples and standards were added and the plate incubated for 1 hour at 300 rpm. The plate was washed 3 times then 25 μl of detection antibody added and the plate incubated for 30 min. After washing, 50 μl of 1X Streptavidin-PE (Phycoerythrin) was added to each well and incubated for 10 min. The plate was again washed and resuspended in 125 μl of assay buffer for reading using Bio-plex manager software (version 4.0) and a low photomultiplier tube setting.

Statistical analysis

Cytokine levels were log transformed and analysed within groups.
pre- and post-vaccination using a paired Wilcoxon signed rank test. Levels were compared between BCG scar positive and scar negative subjects using a Mann-Whitney U-test and corrected for multiple comparisons.

Results

Plasma cytokine concentration for BCG scar negative subjects following MVA85A vaccination

The majority of cytokines measured were either low (IFN-γ, TNF-α, IL-7, IL-12, IL-4, IL-5, IL-10, IL-13, IL-17, G-CSF) or undetectable before and after vaccination with MVA85A (IL-1β, IL-2, IL-6). Nevertheless, we saw detectable levels of IL-18 (median [IQR]=51[27-97] pg/mL), MCP-1 (66[51-76] pg/mL) and MIP-1β (76[65-101] pg/mL) prior to vaccination (Table 1, Figures 1A-C). Following vaccination of the scar-negative subjects no change in IL-18 was seen but MCP-1 and MIP-1β concentrations were both significantly lower (52[41-65]; p=0.0098 and 69[62-102] pg/mL; p=0.0244 respectively).

Plasma cytokine concentration for BCG scar positive subjects following MVA85A vaccination

As seen with the BCG scar negative subjects, the majority of cytokines measured before vaccination were either low (IFN-γ, TNF-α, IL-7, IL-12, IL-4, IL-5, IL-10, IL-13, IL-17, G-CSF) or undetectable (IL-1β, IL-2, IL-6). Plasma concentration of most cytokines and chemokines did not change after vaccination except for IL-8 and MIP-1β which both increased significantly after vaccination (median [IQR]=77[57-87] pg/mL) and 25[17-37] pg/mL pre-vaccination for MIP-1β and 43[31-199] pg/mL post-vaccination for IL-8 (Table 1 and Figures 1C and 1D). There was also a small but observable decrease in IFN-γ concentrations post-vaccination (4.3[0-18] pg/mL pre- and 2.6[0-3.5] pg/mL post-vaccination; p=0.0422; Table 1 and Figure 1E).

Figure 1: Cytokine and chemokine concentrations of BCG scar negative and scar positive healthy adult subjects pre and post vaccination. Pre-vaccination (filled) and post-vaccination (open). Cytokine levels were analysed within groups using a paired Wilcoxon signed rank test. Levels were compared between BCG scar positive and scar negative subjects using a Mann-Whitney U-test. P-values are indicated. Line = median.
Comparison of pre- and post-vaccination concentrations between BCG scar positive and negative subjects

We next compared the cytokine concentrations for BCG scar-negatives and scar-positive subjects. While most cytokines were similar between the groups, IL-8 was significantly higher in scarpositive subjects compared to scar-negative subjects both before and after vaccination with MVA85A (p=0.0377 and p=0.0092 respectively; Figure 1B). Conversely, MCP-1 was significantly lower in scar-positive compared to scar-negative subjects both before and after vaccination (p=0.0005 and p=0.0043 respectively; Figure 1B). Furthermore, IL-12(p70) and IL-17 were both lower in scar-positive compared to scar-negative subjects after vaccination (p=0.0027 and p=0.0404 respectively; Figures 1A and 1F).

Discussion

We assessed the effects of MVA85A vaccination on plasma cytokine levels depending on prior BCG status. In subjects with a BCG scar, MVA85A vaccination resulted in increases in IL-8 and MCP-1 but a decrease in IFN-γ. In contrast, a decrease in both MCP-1 and MIP-1β levels were seen following MVA85A vaccination of BCG scar-negative subjects. Interestingly, the concentration of MCP-1, IL-12(p70) and IL-17 were all higher at post-vaccination in the BCG scar negative subjects compared to the BCG scar positive subjects whilst the reverse was the case for IL-8. These findings suggest that MVA85A has a differential effect on the immune system depending on prior BCG vaccination status.

We have previously reported that vaccination with MVA85A induces comparable immune responses to Antigen 85A and PPD regardless of BCG status in Gambian adult subjects [7]. In contrast BCG scar positive subjects from the United Kingdom mounted a higher response to BCG naïve subjects suggesting the threshold of responses is affected by environmental mycobacteria [6].

Cytokines and chemokines play a major role in the immune response to many infections. IL-8 is produced by macrophages and is one of the major mediators of the inflammatory response [9]. IL-8 was consistently higher in subjects with a BCG scar both before and after MVA85A vaccination. This reflects a boost effect of MVA85A on IL-8 suggesting that MVA is a proinflammatory agent. MCP-1 is required to attract monocytes and dendritic cells to sites of tissue inflammation and MIP-1β acts to induce activation of the macrophages [10,11]. Both these factors were lower after vaccination in BCG scar-positive subjects. Post-vaccination levels of IL-18 and IL-12(p70) were also significantly lower in subjects who had received prior BCG vaccination. These results clearly show that in a TB endemic country setting, prior BCG vaccination modifies the response to MVA85A due to the pre-existing cytokine milieu. However, within subject groups, the scar negative group showed a decrease in MCP-1 and MIP-1β with no other changes observed whereas the scar-positive group showed increases in MIP-1β and IL-8.

In conclusion, immunization with MVA85A induces differential changes in cytokines and chemokines which are dependent on prior BCG vaccination status. However, in the absence of defined immunological correlates of protection, the relevance of these findings for efficacy will only become clear when the results of ongoing trials are known.

Acknowledgements

We acknowledge the contributions of Adama Bojang and Abdulrahman Hammond and the TB Immunology lab staff. We also acknowledge the support of the Management of MRC Laboratories especially the former head of Bacterial Diseases Programme, Prof. Richard Adegbola. Above all we thank the study participants and their families.

Funding

The study was funded by the Medical Research Council (UK) and the European Commission (AFTB-VAC-IC4-CT-2002-10052). Neither funder had any role in the design of the study or the preparation of the manuscript.

References
